Association between vascular comorbidity and progression of Alzheimer’s disease: a two-year observational study in Norwegian memory clinics
Tóm tắt
Vascular risk factors increase the risk of Alzheimer’s disease (AD), but there is limited evidence on whether comorbid vascular conditions and risk factors have an impact on disease progression. The aim of this study was to examine the association between vascular disease and vascular risk factors and progression of AD. In a longitudinal observational study in three Norwegian memory clinics, 282 AD patients (mean age 73.3 years, 54% female) were followed for mean 24 (16–37) months. Vascular risk factors and vascular diseases were registered at baseline, and the vascular burden was estimated by the Framingham Stroke Risk Profile (FSRP). Cerebral medical resonance images (MRIs) were assessed for white matter hyperintensities (WMH), lacunar and cortical infarcts. The associations between vascular comorbidity and progression of dementia as measured by annual change in Clinical Dementia Rating Sum of Boxes (CDR-SB) scores were analysed by multiple regression analyses, adjusted for age and sex. Hypertension occurred in 83%, hypercholesterolemia in 53%, diabetes in 9%, 41% were overweight, and 10% were smokers. One third had a history of vascular disease; 16% had heart disease and 15% had experienced a cerebrovascular event. MRI showed lacunar infarcts in 16%, WMH with Fazekas score 2 in 26%, and Fazekas score 3 in 33%. Neither the vascular risk factors and diseases, the FSRP score, nor cerebrovascular disease was associated with disease progression in AD. Although vascular risk factors and vascular diseases were prevalent, no impact on the progression of AD after 2 years was shown.
Tài liệu tham khảo
Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, et al. Dementia prevention, intervention, and care. Lancet. 2017;
Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, Knopman DS, Mintz A, Rahmim A, Sharrett AR, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443–50.
Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging. 2000;21(1):57–62.
Kruyer A, Soplop N, Strickland S, Norris EH. Chronic hypertension leads to Neurodegeneration in the TgSwDI mouse model of Alzheimer’s disease. Hypertension. 2015;66(1):175–82.
Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P, Mo H, et al. Cerebral blood flow in Alzheimer’s disease. Vasc Health Risk Manag. 2012;8(1):599–611.
Economos A, Wright CB, Moon YP, Rundek T, Rabbani L, Paik MC, Sacco RL, Elkind MS. Interleukin 6 plasma concentration associates with cognitive decline: the northern Manhattan study. Neuroepidemiology. 2013;40(4):253–9.
Walker KA, Hoogeveen RC, Folsom AR, Ballantyne CM, Knopman DS, Windham BG, Jack CR Jr, Gottesman RF. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC study. Neurology. 2017;89(22):2262–70.
Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Amyloid Biomarker Study G, Aalten P, Aarsland D, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–38.
Blom K, Emmelot-Vonk MH, Koek HL. The influence of vascular risk factors on cognitive decline in patients with dementia: a systematic review. Maturitas. 2013;76(2):113–7.
Li J, Cesari M, Liu F, Dong B, Vellas B. Effects of diabetes mellitus on cognitive decline in patients with Alzheimer disease: a systematic review. Can J Diabetes. 2017;41(1):114–9.
Bergland AK, Dalen I, Larsen AI, Aarsland D, Soennesyn H. Effect of vascular risk factors on the progression of mild Alzheimer’s disease and Lewy body dementia. J Alzheimers Dis. 2017;56(2):575–84.
Qiao J, Lu WH, Wang J, Guo XJ, Qu QM. Vascular risk factors aggravate the progression of Alzheimer’s disease: a 3-year follow-up study of Chinese population. Am J Alzheimers Dis Other Demen. 2014;29(6):521–5.
Blom K, Vaartjes I, Peters SA, Koek HL. The influence of vascular risk factors on cognitive decline in patients with Alzheimer’s disease. Maturitas. 2014;79(1):96–9.
Bos I, Vos SJ, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Engelborghs S, Niemantsverdriet E, et al. The frequency and influence of dementia risk factors in prodromal Alzheimer’s disease. Neurobiol Aging. 2017;56:33–40.
Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s coordinating Centre. Brain. 2013;136(Pt 9):2697–706.
Mok VC, Lam BY, Wong A, Ko H, Markus HS, Wong LK. Early-onset and delayed-onset poststroke dementia - revisiting the mechanisms. Nat Rev Neurol. 2017;13(3):148–59.
White LR, Edland SD, Hemmy LS, Montine KS, Zarow C, Sonnen JA, Uyehara-Lock JH, Gelber RP, Ross GW, Petrovitch H, et al. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia aging studies. Neurology. 2016;86(11):1000–8.
Brickman AM. Contemplating Alzheimer’s disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep. 2013;13(12):415.
Prins ND, van der Flier WM, Brashear HR, Knol DL, van de Pol LA, Barkhof F, Scheltens P. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. J Alzheimers Dis. 2013;36(1):79–85.
Stefanidis KB, Askew CD, Greaves K, Summers MJ. The effect of non-stroke cardiovascular disease states on risk for cognitive decline and dementia: a systematic and meta-analytic review. Neuropsychol Rev. 2017;
Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, Weiss JP, Lappe DL, Bunch TJ. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacing Clin Electrophysiol. 2009;32(5):648–52.
Rajendiran KS, Ananthanarayanan RH, Satheesh S, Rajappa M. Elevated levels of serum sialic acid and high-sensitivity C-reactive protein: markers of systemic inflammation in patients with chronic heart failure. Br J Biomed Sci. 2014;71(1):29–32.
Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045–51.
Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007;69(19):1850–8.
Harrison SL, Ding J, Tang EY, Siervo M, Robinson L, Jagger C, Stephan BC. Cardiovascular disease risk models and longitudinal changes in cognition: a systematic review. PLoS One. 2014;9(12):e114431.
Viticchi G, Falsetti L, Buratti L, Boria C, Luzzi S, Bartolini M, Provinciali L, Silvestrini M. Framingham risk score can predict cognitive decline progression in Alzheimer’s disease. Neurobiol Aging. 2015;36(11):2940–5.
Viticchi G, Falsetti L, Buratti L, Sajeva G, Luzzi S, Bartolini M, Provinciali L, Silvestrini M. Framingham risk score and the risk of progression from mild cognitive impairment to dementia. J Alzheimers Dis. 2017;59(1):67–75.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939–44.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. J Intern Med. 2004;256(3):240–6.
Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–8.
Eldholm RS, Barca ML, Persson K, Knapskog AB, Kersten H, Engedal K, Selbaek G, Braekhus A, Skovlund E, Saltvedt I. Progression of Alzheimer’s disease: a longitudinal study in Norwegian memory clinics. J Alzheimers Dis. 2018;61(3):1221–32.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.
Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81(3):815–20.
Dufouil C, Beiser A, McLure LA, Wolf PA, Tzourio C, Howard VJ, Westwood AJ, Himali JJ, Sullivan L, Aparicio HJ, et al. Revised Framingham stroke risk profile to reflect temporal trends. Circulation. 2017;135(12):1145–59.
Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967–72.
Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, et al. Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology. Neuroepidemiology. 2005;24(1–2):51–62.
Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, Mungas D, Reed BR, Kramer JH, Decarli CC, et al. Cognitive impact of subcortical vascular and Alzheimer’s disease pathology. Ann Neurol. 2006;60(6):677–87.
Jellinger KA, Attems J. Prevalence and impact of cerebrovascular pathology in Alzheimer’s disease and parkinsonism. Acta Neurol Scand. 2006;114(1):38–46.
Nordestgaard LT, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Body mass index and risk of Alzheimer’s disease: a mendelian randomization study of 399,536 individuals. J Clin Endocrinol Metab. 2017;102(7):2310–20.
Boyle PA, Yang J, Yu L, Leurgans SE, Capuano AW, Schneider JA, Wilson RS, Bennett DA. Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain. 2017;140(3):804–12.
Krokstad SK, Skjei M. Public health development. The HUNT study, Norway. HUNT 1 (1984–86) - HUNT2 (1995–97) - HUNT 3 (2006–08). In: HUNT research center. Levanger: HUNT research center; 2011. p. 213.
Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from Central Norway. BMC Neurol. 2008;8:9.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455–532.